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Abstract
Background: To investigate the clinical relevance of two different preservative formulations, we compared 1-year
incidence rates of additional coding of dry eye, ocular infection, or ocular surface disease (either dry eye or ocular
infection) in open-angle glaucoma and ocular hypertension patients newly treated with latanoprost with
benzalkonium chloride (BAK) or with travoprost-Z with SofZia
®.
Methods: This was a retrospective study of three U.S.-based patient-centric medical/pharmacy claims databases
(MedStat, PharMetrics, i3-Ingenix). Patients were eligible if they filled a prescription for latanoprost or travoprost-Z
between October 2006 and Q2 2008 (prescription date = index date) AND were continuously enrolled 6 months
prior through 12 months after the index date AND had any open-angle glaucoma or ocular hypertension diagnosis
within 90 days prior to the index date AND did not have an ocular surface disease diagnosis during the 180 days
prior to the index date AND if they had not had a prescription for the index agent in the 180 days prior to the
index date. Time to incidence of new coding for ocular surface disease in the first year post-index was estimated
with a composite endpoint: diagnosis of dry eye or ocular infection by ICD-9-CM or Current Procedural
Terminology code OR by prescription for cyclosporine ophthalmic emulsion or ocular antibiotics.
Results: In all, 15,933 patients were treated with latanoprost and 7670 with travoprost-Z. Over 1 year, 4.3% of
latanoprost and 4.5% of travoprost-Z patients were identified with dry eye (p = 0.28), and 10.9% and 11.1%,
respectively, were identified with an ocular infection (p = 0.79). The 1-year incidence of new coding for ocular
surface disease also was similar across treatments (13.9% vs 14.3%, respectively; p = 0.48).
Conclusions: The retrospective analysis of three large prescription databases revealed that open-angle glaucoma
and ocular hypertension patients newly treated with latanoprost preserved with BAK or travoprost-Z preserved
with SofZia did not differ statistically in rates of dry eye, ocular infection, or ocular surface disease (either dry eye or
ocular infection) during the first year post-index. Claims-based analyses are limited by nonrandomization and the
inability to account for over-the-counter use or samples.
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Ocular surface disease is an umbrella term that encom-
passes both dry eye disease (e.g., aqueous deficient and
evaporative) and non-dry eye disease (e.g., lid-related
diseases, allergic conjunctivitis, infective and noninfec-
tive keratitis) [1]. A question remains as to whether
commercial preservatives used in ocular hypotensive eye
drops administered by patients with open-angle glau-
coma or ocular hypertension affect the occurrence of
ocular surface disease, in particular the occurrence of
dry eye and/or ocular infection, when the clinical evi-
dence from randomized, controlled trials suggests there
is no clear link [2-4].
All preservatives have the potential to cause corneal
and conjunctival changes, including possibly dry eye.
The prevalence of clinically diagnosed dry eye among
glaucoma patients in general and among those treated
with ocular hypotensive agents containing benzalko-
nium chloride (BAK) remains unclear [5,6], although
relatively few patients included in pivotal trials of
bimatoprost, latanoprost, and travoprost, all of which
contain BAK, reported dry eye (1% to 4% for latano-
prost and travoprost; 3% to 10% for bimatoprost) [2-4].
Moreover, removing BAK from a prostaglandin analog
or using an alternative preservative may not reduce the
occurrence of dry eye. A double-masked, randomized,
parallel group trial [7] that compared the safety and
tolerability of travoprost with BAK versus that of tra-
voprost-Z with SofZia
®, an ionic buffered system com-
posed of boric acid, propylene glycol, sorbitol, and zinc
chloride, found no statistically or clinically significant
between-treatment differences with regard to ocular
adverse events or tolerability; the prevalence of dry eye
w a s1 . 7 %w i t ht r a v o p r o s t - Zv e r s u s2 . 0 %w i t ht r a v o -
prost [8].
With regard to infection, preservatives protect against
potentially dangerous bacterial and fungal organisms
that may be introduced inadvertently into multiple-
dose containers during eye drop instillation, especially
with larger size bottles (e.g., 5 mL, 7.5 mL) [9-11]. The
bactericidal and fungicidal activity of preservatives
helps ensure ocular safety, an especially important con-
sideration given the increase in bacterial resistance to
antibiotic treatment of ocular infections [12,13] and
t h ed r a m a t i cr i s ei nt h ei n c i d e n c eo ff u n g a lk e r a t i t i s
[14-17]. Although these reported outbreaks of fungal
keratitis occurred in contact lens wearers and we are
not aware of published data suggesting that different
preservatives may be associated with outbreaks with
chronic use of ocular hypotensive medications, the dra-
matic rise in the incidence of the condition highlights
the importance of using preservatives that comply with
stringent standards of antimicrobial activity in multi-
dose containers.
To investigate the clinical relevance of two different
preservative formulations, we compared 1-year incidence
rates of additional coding of dry eye, ocular infection,
and ocular surface disease, defined as either dry eye or
ocular infection, in open-angle glaucoma and ocular
hypertension patients newly treated with latanoprost
with BAK or travoprost-Z with SofZia.
Methods
This was a retrospective analysis of information from
three U.S.-based patient-centric medical and pharmacy
claims databases: MedStat, PharMetrics, and i3-Ingenix.
Together, these databases contain information from
managed care organizations consisting of over 123.5
million patients. The data represent a systematic sample
of commercial health plan information obtained from
managed care plans throughout the U.S. It is paid claims
data, which by definition is information collected by the
medical plans from medical service providers to facili-
tate the adjudication and payment of health insurance
benefits on behalf of the plan’s enrolled members. The
databases were deidentified in accordance with Health
Insurance Portability and Accountability Act require-
ments prior to being made available for analysis in this
study; use of these data in health research is exempt
from institutional review board review.
Condition identifiers are provided in Table 1. Open-
angle glaucoma and ocular hypertension were defined
by ICD-9-CM codes, while dry eye, ocular infection, and
the ocular surface disease composite endpoint reflecting
either dry eye or ocular infection were defined by ICD-
9-CM codes, Current Procedural Terminology [CPT]
codes and/or prescriptions.
The derivation of the analysis population is summar-
ized in Table 2. The patient’sf i l ld a t ef o rl a t a n o p r o s to r
travoprost-Z was considered to be the index date.
Patients were eligible for inclusion if the index date was
between October 2006, when travoprost-Z was intro-
duced in the U.S., and the second quarter of 2008 AND
if they were continuously enrolled 6 months prior
through 12 months after the index date AND if they
had any open-angle glaucoma or ocular hypertension
diagnosis within 90 days prior to the index date AND if
they did not have a diagnosis of ocular surface disease
during the 180 days prior to the index date AND if they
had not had a prescription for the index agent in the
180 days prior to the index date. Of the more than
264,000 potentially eligible patients across the three
databases, 23,603 were included in the analysis
population.
Frequencies of patients in the latanoprost and travo-
prost-Z groups diagnosed with dry eye, ocular infection,
or ocular surface disease during 1 year of follow-up
were tabulated separately and compared using Cochran-
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Page 2 of 10Table 1 Identifiers of Conditions
Condition Identifier Heading
Open-angle glaucoma ICD-9-CM: Open-angle glaucoma
365.11
Ocular hypertension ICD-9-CM: Ocular hypertension
365.04
Dry eye Prescription* Restasis (cyclosporine ophthalmic emulsion)
ICD-9-CM:
370.20
370.21 Superficial keratitis, unspecified
370.33 Punctate keratitis
370.8
† Keratoconjunctivitis Sicca not specified as Sjogren’s
370.9
† Other forms of keratitis
372.20
† Unspecified keratitis
372.39
† Blepharoconjunctivitis
375.15 Other conjunctivitis
710.2 Tear film insufficiency unspecified
CPT: Sicca syndrome
68760
68761 Closure of lacrimal punctum; by thermocauterization ligation or laser surgery
Closure of lacrimal punctum by plug
Infection Prescription* Bacitracin (bacitracin); Bleph-10; Cetamide; Chibroxin; Ciloxan (ciprofloxacin); Erythromycin;
Levaquin (levofloxacin); Neomycin; Neosporin; Oculflox (ofloxacin); Ocusulf-10; Sodium
Sulamyd; Sulf-10; Tobradex; Vigamox (moxifloxacin); Zymar
ICD-9-CM:
370.00
370.8
† Corneal ulcer unspecified
370.9
† Other forms of keratitis
372.00 Unspecified keratitis
372.03 Acute conjunctivitis
372.20
† Other mucupurulent conjunctivitis
372.30 Blepharoconjunctivitis
372.39
† Conjunctivitis unspecified
Other conjunctivitis
Ocular Surface Disease
Composite Endpoint
Any identifier of dry eye or
ocular infection
*Generic drug name in parenthesis where applicable.
†ICD-9-CM code applicable for both dry eye and infection.
CPT = Current Procedural Terminology; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.
Table 2 Derivation of analysis population
Database
MedStat PharMetrics i3-Ingenix Total
All patients in the database 41,105,604 >60,000,000 22,689,623 >123,795,227
And filled prescription for latanoprost or travoprost-Z 10/2006 - Q2/2008 152,961 69,298 42,424 264,683
And continuous enrollment 6 months prior through 12 months after index date 84,871 35,447 23,091 143,409
And any open-angle glaucoma or ocular hypertension* diagnosis within 90 days
prior to index date
31,760 14,713 9107 55,580
And no ocular surface disease* during 180 days prior to index date 28,711 12,833 7597 49,141
And no prescription for the index agent in 180 days prior to index date 15,154 4151 4298 23,603
*Defined in Table 1.
Index date = date of initial prescription for latanoprost or travoprost-Z; Q2 = second quarter.
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by indicator of condition. Kaplan-Meier and Cox pro-
portional hazards survival analyses of time to occurrence
of dry eye, ocular infection, or ocular surface disease
were performed. The statistical significance of between-
group differences in time to occurrence of each end-
point was assessed using the Cox proportional hazards
model that included treatment, age, gender, Charlson
Comorbidity Index (which is used routinely to charac-
terize the health status of patients in administrative
databases [18]), geographic region, diagnosis, and claims
database as predictors. P-values for age and Charlson
Comorbidity Index are from an analysis of variance
model that included treatment, database, and treatment
by database interaction. P-values for diagnosis, gender,
and geographic region are from Cochran-Mantel-Haens-
zel tests stratified by database.
Results
The analysis set included 15,933 patients prescribed
latanoprost and 7670 patients prescribed travoprost-Z.
Patients prescribed the two prostaglandins were similar
with regard to gender and geographic region; a larger
proportion of latanoprost-treated patients was diagnosed
with ocular hypertension, and, on average, those in the
latanoprost group were older and had a higher score on
the Charlson Comorbidity Index (Table 3).
Over 1 year, 4.3% of latanoprost and 4.5% of travo-
prost-Z patients were identified with dry eye (p = 0.28),
and 10.9% and 11.1%, respectively, were identified with
an ocular infection (p = 0.79; Table 4). The 1-year inci-
dence of new coding for ocular surface disease also was
similar across treatments (13.9% vs 14.3%, respectively;
p = 0.48). Among the 3,306 ocular surface disease
events, there was no statistically significant between-
treatment difference in proportions of patients develop-
ing the condition when it was indicated by diagnosis,
CPT code, or prescription (Table 5).
Kaplan-Meier survival curves for time to dry eye,
infection, and ocular surface disease were nearly identi-
cal for latanoprost and travoprost-Z overall (Figure 1 A,
B, and 1C, respectively) and when stratified by database
(Figure 2 A, B, and 2C, respectively. Curves also were
virtually identical when ocular surface disease was indi-
cated by diagnosis, CPT code, or prescription (Figure
3A, B, and 3C, respectively). Mean time to an ocular
surface disease event among patients with events was
approximately 5 months in both groups (latanoprost:
164.0 ± 104.8 days; travoprost-Z: 160.4 ± 104.3 days).
Discussion
When choosing an ocular hypotensive agent for patients
with open-angle glaucoma or ocular hypertension, phy-
sicians should consider the efficacy of candidate medica-
tions, their tolerability and side effect profiles, as well as
any concomitant ocular and systemic conditions the
patient may have [19]. With the advent of new preserva-
tive formulations, it also is essential that clinicians famil-
iarize themselves with the body of evidence regarding
the long-term safety and efficacy of the preservatives
contained in ophthalmic solutions. Our analysis of three
large prescription databases found that open-angle glau-
coma and ocular hypertension patients newly treated
with latanoprost containing BAK were not significantly
more likely to develop dry eye, ocular infection, or ocu-
lar surface disease (either dry eye or ocular infection) as
evidenced by additional coding for these disorders dur-
ing the first year of treatment than were patients newly
treated with travoprost-Z containing SofZia.
BAK, which has been used as a preservative for more
than 50 years, is among the few preservatives that meet
the rigorous criteria required by both the United States
Pharmacopoeia (USP) and the European Pharmacopoeia
[20,21]. SofZia, approved by the Food and Drug Admin-
istration in 2006, also meets USP standards, but little is
published about its pharmacokinetics and pharmacody-
namics [22]. There is contradicting evidence concerning
Table 3 Patient characteristics
Characteristic Latanoprost
N = 15,933
Travoprost-Z
N = 7670
p-value
Diagnosis, n (%) <0.0001
Open-angle glaucoma 13,918 (87.4) 6837 (89.1)
Ocular hypertension 2015 (12.6) 833 (10.9)
Sex, n (%)* 0.55
Female 8413 (52.8) 4008 (52.3)
Male 7519 (47.2) 3662 (47.7)
Age, years: Mean ± SD 67.4 ± 13.3 66.3 ± 13.0 <0.0001
Charlson Comorbidity Index:
Mean ± SD 0.74 ± 1.25 0.67 ± 1.15 <0.0001
Geographic region
† 0.17
Northeast 2914 (18.3) 1071 (14.0)
Midwest 5004 (31.4) 2440 (31.9)
South 5270 (33.1) 2756 (36.0)
West 2728 (17.1) 1387 (18.1)
*Missing data for 1 latanoprost patient.
†Missing data for 17 latanoprost and 16 travoprost-Z patients.
SD = standard deviation.
Table 4 One-year incidence of new coding for dry eye
ocular infection, or both dry eye and ocular infection,
* n (%)
Index drug Total patients Dry eye Ocular infection Both
Latanoprost 15,933 600 (3.8) 1670 (10.5) 60 (0.4)
Travoprost-Z 7670 298 (3.9) 821 (10.7) 23 (0.3)
p-value - 0.48 0.86 0.31
*Categories are not mutually exclusive. See Table 1 for definitions of dry eye
and ocular infection.
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surface disorders. Dose-dependent, BAK-induced
epithelial cellular damage has been found in studies of
cultured corneal [23] and conjunctival cells [24] as well
as in studies of cats and rabbits [25-28], but these stu-
dies may not accurately reflect ocular surface condi-
tions in humans. Others [29-33] have shown that the
levels of BAK contained in ophthalmic solutions are
unlikely to cause clinically important negative corneal
effects. Determining the relationship between BAK and
dry eye in glaucoma patients is made more problematic
by the fact that the incidence of both conditions
increases with age [34,35], although history of glau-
coma has not been found to be an independent risk
factor for dry eye [36].
While preservative-free ocular hypotensive eye drops
generally have been associated with fewer side effects
[37-42] and better stability of the tear film [40,43] than
drops containing a preservative, preservatives are added
to ophthalmic preparations that are instilled multiple
times in order to control microbial growth and to pre-
vent the consequences associated with the use of con-
taminated solutions [21,44]. Serious infections can result
from the instillation of contaminated eye preparations.
Pathogenic contamination of eye drops is a significant
risk factor for several complications, including infectious
keratitis [21], although we know of no published data
suggesting that different preservatives may be associated
with outbreaks of this condition with chronic use of
glaucoma medications.
T h ei m p o r t a n c eo fd e t e r m i ning the clinical impact of
alternative preservatives in ocular hypotensive eye drops
reflects the need to reduce the risk of ocular infection
while limiting side-effects such as dry eye that might
reduce patient adherence and persistence. Although we
found no statistically significant difference in the 1-year
incidence of ocular surface disease in more than 23,000
patients treated with either latanoprost or travoprost-Z,
other studies [45-48] have yielded disparate results, at
least in part due to differences in methodologies and
measures, and, in some cases [46-48], to small samples
and low power to detect differences if they existed. For
example, a multicenter, investigator-masked, parallel-
group study [47] of patients with glaucoma or ocular
hypertension who had been treated with latanoprost
monotherapy for at least 4 weeks were randomized to
receive monotherapy with bimatoprost with BAK (n =
35), latanoprost with BAK (n = 38), or travoprost with
SofZia (n = 33). Across 3 months of follow-up, no sig-
nificant between-treatment differences were noted in
conjunctival hyperemia scores, corneal staining, or tear
breakup time. A randomized, double-blind study [48]
compared tolerability in 33 patients treated with latano-
prost in one eye and travoprost-Z in the other. Eyes
were assessed by one examiner every 3 to 4 weeks for 3
months, and patients rated the extent of differences
between eyes in ocular dryness/irritation at the begin-
ning and at the end of the study. In this small sample,
eyes treated with travoprost-Z had significantly more
corneal staining (p = 0.025) and showed a trend toward
more dryness and irritation symptoms than those trea-
ted with latanoprost (p = 0.095). A prospective, 8-week,
unmasked, single-center study [46] of 40 eyes of 20
patients with low baseline tear break-up times who were
switched from latanoprost to travoprost-Z found a sig-
nificant increase (p < 0.001) in mean tear break-up time
and a significant decrease (p < 0.001) in the mean Ocu-
lar Surface Disease Index score. The authors noted that
the study focused on patients with low initial tear
break-up times, limiting generalizability to the entire
population of patients with dry eye; the lack of blind-
i n g ,t h ea b s e n c eo fac o m p a r i s o ng r o u p ,a n dt h ep o t e n -
tial for regression to the mean also were limitations. A
prospective, open-label, 3-month study [45] of 691
patients switched to travoprost-Z from latanoprost or
bimatoprost due to tolerability issues found clinically
and statistically significant improvement in ocular sur-
face disease symptoms. The study was limited by the
facts that open-label, switch designs do not control for
expectations of improvement on the part of both
patients and physicians, and by its short follow-up time
frame.
As with all research, the present study has both
strengths and limitations. Primary strengths include the
large sample size. However, this was a retrospective ana-
lysis in which patients were not randomized, a basic
Table 5 One-year incidence of new coding for ocular surface disease (OSD) by indicator of condition, n (%)
OSD indicated by*
Total Diagnosis (ICD-9-CM) CPT Code Prescription
Index drug No OSD OSD No OSD OSD No OSD OSD No OSD OSD
Latanoprost 13,723 (86.1) 2210 (14.0) 15,127 (94.9) 806 (5.1) 15,849 (99.5) 84 (0.5) 14,275 (89.6) 1658 (10.4)
Travoprost-Z 6574 (85.6) 1096 (14.3) 7279 (94.9) 391 (5.1) 7616 (99.3) 54 (0.7) 6832 (89.1) 838 (10.9)
p-value 0.48 0.66 0.13 0.42
*Categories are not mutually exclusive. See Table 1 for definition of ocular surface disease composite endpoint.
CPT = Current Procedural Terminology; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.
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over-the-counter products and samples as well as off-
label use of topical corticosteroids to treat dry eye were
not reflected in the database. The proportion of patients
recommended to use artificial tears cannot be
determined using a database analysis. Because this was a
claims-based analysis rather than a clinical trial, we
could not directly measure dry eye syndrome but
instead measured the addition of a second code for one
of many ocular surface diseases; we cannot estimate the
Figure 1 Days to dry eye (A), infection (B), and ocular surface disease composite endpoint (C) by treatment group
Schwartz et al. BMC Ophthalmology 2011, 11:14
http://www.biomedcentral.com/1471-2415/11/14
Page 6 of 10frequency with which physicians omitted a relevant sec-
ond code or patients added an artificial tear supplement
without the knowledge of the physician. Identifying dry
eye using CPT and ICD-9-CM codes may select for
more severe cases of the condition. It is possible that
the populations of patients using the two compounds
could have been different since travoprost-Z has been
specifically marketed and may have been chosen in
some individuals who might already have mild, non-
coded ocular surface disease prior to 180 days or who
Figure 2 Days to dry eye (A), infection (B), and ocular surface disease composite endpoint (C) by database
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Page 7 of 10had a history of ocular surface symptoms that were not
specifically coded for in the study. Not accounted for
were any diagnosis that was made >180 days prior to
the index date and that might not have been coded for
as the subject developed glaucoma or the physician only
coded for one, not two diseases which is quite common.
In addition, although a glaucoma specialist (GFS)
r e v i e w e da n da p p r o v e dt h ec o d e su s e dt oi d e n t i f yt h e
clinical endpoints evaluated, other specialists might
argue for the inclusion of other identifiers and/or the
Figure 3 Days to ocular surface disease indicated by diagnosis (A), procedures (CPT code) (B), or prescription (C) by treatment group
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Page 8 of 10exclusion of some used herein; to our knowledge, there
is no widely accepted set of identifiers for the general
conditions of dry eye, ocular infection, or ocular surface
disease.
Conclusion
Results of the present retrospective analysis of three
large prescription databases suggest that open-angle
glaucoma and ocular hypotensive patients newly treated
with latanoprost with BAK or with travoprost-Z con-
taining SofZia do not differ statistically in rates of cod-
ing for dry eye, ocular infection, or ocular surface
disease (either dry eye or ocular infection), during the
first year post-index. Prospective, randomized, ade-
quately powered comparisons of similarly effective ocu-
lar hypotensive agents with different preservatives
are needed to more definitively answer the question
of the clinical relevance of alternative preservative
formulations.
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